Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 in HIV infected adult females living in the Republic of South Africa. The study is double blinded, randomized for HIV positive subjects and open for HIV negative subjects. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month
B: Arm Label: Gardasil®; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Arm Label: Cervarix®; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil® | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix®
C: Arm Label: Girls 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Boys 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls and Boys 9 to 14 Years V503 at Months 0 and 12; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls 9 to 14 Years V503 at Months 0, 2, and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Young Women 16 to 26 Years V503 at Months 0, 2, and 6; Type: ACTIVE_COMPARATOR; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Intervention Type: BIOLOGICAL; Name: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine); Assigned to Arm(s): Boys 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0, 2, and 6, Girls and Boys 9 to 14 Years V503 at Months 0 and 12, Young Women 16 to 26 Years V503 at Months 0, 2, and 6
D: Arm Label: HIV+/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: HIV+/Aluminium Hydroxide Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo Control | Arm Label: HIV-/Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): HIV+/Cervarix Group, HIV-/Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): HIV+/Aluminium Hydroxide Group

Answer: D